N. V. Kirichenko
Research Subjects
N. V. Kirichenko has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Alexey Viktorovich Taganov
Russian Medical Academy of Continuous Professional Education
3 shared publications - Elena N. Simakina
Clinical Hospital No. 1
3 shared publications - Kira Ya. Zaslavskaya
National Research Ogarev Mordovia State University
3 shared publications - Larisa Aleksandrovna Balykova
N.P. Ogarev Mordovia State University
3 shared publications - Natalia M. Selezneva
National Research Ogarev Mordovia State University
3 shared publications - Dmitrii Yu. Pushkar
Russian University of Medicine
2 shared publications
Latest Publications
- Open Access
- 4 September 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 13 (4) , 297-315
Molnupiravir in the treatment of patients with influenza or acute respiratory viral infections: a multicenter comparative randomized double-blind placebo-controlled trial
The aim. To evaluate the efficacy and safety of molnupiravir compared to placebo in patients with influenza and/or ARVI.Materials and methods. The study involved 300 patients. The study included patients aged 18 to 80 years with clinical signs of influenza/ARVI (duration no more than 48 hours): elevated body temperature ≥37.5℃ and the presence of at least 2 symptoms of moderate severity (chills, headache, myalgia, sore throat, nasal congestion, runny nose, sneezing, cough, with laboratory-confirmed diagnosis of influenza/ARVI at the time of screening), meeting the selection criteria for the study. Group 1 (n=150) received the investigational medicine molnupiravir (Esperavir®, Promomed Rus LLC, Russia) 800 mg (4 capsules) 2 times/day (daily dose 1600 mg) for 5 days; Group 2 (n=150) received placebo 4 capsules 2 times/day for 5 days, then patient observation was carried out until day 14 (4 visits after screening). The effectiveness of therapy was assessed according to primary and secondary efficacy criteria. The primary efficacy criterion was the time (in days) to clinical recovery. Safety was assessed by considering the number and severity of adverse events (AEs) and serious adverse events (SAEs). For the analysis of qualitative indicators, an intergroup comparison of proportions was performed using a two-sided version of Fisher's exact test, or the χ2 ("chi-square") test. For quantitative indicators — using the non-parametric Mann-Whitney test. Differences were considered statistically significant at p Results. According to the results of the assessment of the primary efficacy criterion, it was shown that molnupiravir therapy statistically significantly reduces the time to clinical recovery compared with placebo (p=0.000039). According to secondary efficacy criteria, a statistically significant advantage of therapy with the investigational medicine compared with placebo was also demonstrated in terms of the frequency of patients who achieved clinical recovery at Visits 2 and 3 p=0.0110, p=0.0070), the frequency of virus elimination. Even on the 3rd day of therapy, the frequency of virus elimination in the investigational drug group was 64.7% compared with 40% in the placebo group (ppConclusion. As a result of the phase III clinical study, the efficacy of molnupiravir (Esperavir®, Promomed Rus LLC, Russia) in the treatment of influenza and/or ARVI and the prevention of the risk of developing complications compared with placebo was proven: patients achieved clinical recovery as early as on the 3rd day of therapy. A favorable safety profile was shown, corresponding to the general characteristics of the medicine.
- 4 September 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 13 (4) , 297-315
Open AccessMolnupiravir in the treatment of patients with influenza or acute respiratory viral infections: a multicenter comparative randomized double-blind placebo-controlled trial
The aim. To evaluate the efficacy and safety of molnupiravir compared to placebo in patients with influenza and/or ARVI.Materials and methods. The study involved 300 patients. The study included patients aged 18 to 80 years with clinical signs of influenza/ARVI (duration no more than 48 hours): elevated body temperature ≥37.5℃ and the presence of at least 2 symptoms of moderate severity (chills, headache, myalgia, sore throat, nasal congestion, runny nose, sneezing, cough, with laboratory-confirmed diagnosis of influenza/ARVI at the time of screening), meeting the selection criteria for the study. Group 1 (n=150) received the investigational medicine molnupiravir (Esperavir®, Promomed Rus LLC, Russia) 800 mg (4 capsules) 2 times/day (daily dose 1600 mg) for 5 days; Group 2 (n=150) received placebo 4 capsules 2 times/day for 5 days, then patient observation was carried out until day 14 (4 visits after screening). The effectiveness of therapy was assessed according to primary and secondary efficacy criteria. The primary efficacy criterion was the time (in days) to clinical recovery. Safety was assessed by considering the number and severity of adverse events (AEs) and serious adverse events (SAEs). For the analysis of qualitative indicators, an intergroup comparison of proportions was performed using a two-sided version of Fisher's exact test, or the χ2 ("chi-square") test. For quantitative indicators — using the non-parametric Mann-Whitney test. Differences were considered statistically significant at p Results. According to the results of the assessment of the primary efficacy criterion, it was shown that molnupiravir therapy statistically significantly reduces the time to clinical recovery compared with placebo (p=0.000039). According to secondary efficacy criteria, a statistically significant advantage of therapy with the investigational medicine compared with placebo was also demonstrated in terms of the frequency of patients who achieved clinical recovery at Visits 2 and 3 p=0.0110, p=0.0070), the frequency of virus elimination. Even on the 3rd day of therapy, the frequency of virus elimination in the investigational drug group was 64.7% compared with 40% in the placebo group (ppConclusion. As a result of the phase III clinical study, the efficacy of molnupiravir (Esperavir®, Promomed Rus LLC, Russia) in the treatment of influenza and/or ARVI and the prevention of the risk of developing complications compared with placebo was proven: patients achieved clinical recovery as early as on the 3rd day of therapy. A favorable safety profile was shown, corresponding to the general characteristics of the medicine.
- 17 June 2024
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 18 (2)
Efficacy and Safety of a New Selective Oral Factor Xa Inhibitor Amidine Hydrochloride for Prevention of Thromboembolic Events in Hospitalized Patients with COVID-19: a Multiple-Center Prospective Randomized Controlled Study
OBJECTIVE To evaluate the effectiveness and safety of a new selective oral factor Xa inhibitor amidine hydrochloride (DD217) as compared to enoxaparin sodium in prevention of venous thromboembolic events (VTE) in patients hospitalized with COVID-19. MATERIAL AND METHODS A multipla-center prospective randomized controlled trial AM217_03 (clinicaltrials.gov identifier NCT05185804) included 401 patients hospitalized with the novel coronavirus infection COVID-19. Patients randomized to group 1 (n=198) received amidine hydrochloride orally at a dose of 60 mg once a day. Patients randomized to group 2 (n=202) received enoxaparin sodium subcutaneously at a dose of 40 mg once daily. The primary end point characterizing the effectiveness was the overall number of cases of thromboembolic events, including VTE. The primary endpoint characterizing safety was the incidence of major and clinically significant non-major bleedings during the study therapy (maximum 30 days). RESULTS The efficacy analysis included data from 177 patients in group 1 and 194 in group 2. No thrombotic events as part of the composite primary endpoint was observed during study therapy in the amidine hydrochloride group and was reported in 7 patients in the enoxaparin sodium group (3.61%; p=0.015). At the same time, the proportion of patients requiring intensive care due to worsening COVID-19 or the occurrence of complications during study therapy was 17 (8.7%) in the amidine hydrochloride group and 10 (5.0%) in the enoxaparin group (p=0.14). No major and clinically significant non-major bleeding was registered in the amidine hydrochloride group compared with 1.0% (2 patients) in the enoxaparin sodium group (p=0.499). CONCLUSION In hospitalized patients with COVID-19 who did not require an intensive care stay, oral factor Xa inhibitor amidine hydrochloride 60 mg once daily was noninferior to subcutaneous enoxaparin sodium 40 mg once daily in preventing thromboembolic complications, demonstrating a trend towards superior effectiveness in the prevention of VTE. Amidine hydrochloride demonstrated a safety profile comparable to enoxaparin in relation to major and clinically significant non-major bleeding.
- 17 June 2024
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 18 (2)
Efficacy and Safety of a New Selective Oral Factor Xa Inhibitor Amidine Hydrochloride for Prevention of Thromboembolic Events in Hospitalized Patients with COVID-19: a Multiple-Center Prospective Randomized Controlled Study
OBJECTIVE To evaluate the effectiveness and safety of a new selective oral factor Xa inhibitor amidine hydrochloride (DD217) as compared to enoxaparin sodium in prevention of venous thromboembolic events (VTE) in patients hospitalized with COVID-19. MATERIAL AND METHODS A multipla-center prospective randomized controlled trial AM217_03 (clinicaltrials.gov identifier NCT05185804) included 401 patients hospitalized with the novel coronavirus infection COVID-19. Patients randomized to group 1 (n=198) received amidine hydrochloride orally at a dose of 60 mg once a day. Patients randomized to group 2 (n=202) received enoxaparin sodium subcutaneously at a dose of 40 mg once daily. The primary end point characterizing the effectiveness was the overall number of cases of thromboembolic events, including VTE. The primary endpoint characterizing safety was the incidence of major and clinically significant non-major bleedings during the study therapy (maximum 30 days). RESULTS The efficacy analysis included data from 177 patients in group 1 and 194 in group 2. No thrombotic events as part of the composite primary endpoint was observed during study therapy in the amidine hydrochloride group and was reported in 7 patients in the enoxaparin sodium group (3.61%; p=0.015). At the same time, the proportion of patients requiring intensive care due to worsening COVID-19 or the occurrence of complications during study therapy was 17 (8.7%) in the amidine hydrochloride group and 10 (5.0%) in the enoxaparin group (p=0.14). No major and clinically significant non-major bleeding was registered in the amidine hydrochloride group compared with 1.0% (2 patients) in the enoxaparin sodium group (p=0.499). CONCLUSION In hospitalized patients with COVID-19 who did not require an intensive care stay, oral factor Xa inhibitor amidine hydrochloride 60 mg once daily was noninferior to subcutaneous enoxaparin sodium 40 mg once daily in preventing thromboembolic complications, demonstrating a trend towards superior effectiveness in the prevention of VTE. Amidine hydrochloride demonstrated a safety profile comparable to enoxaparin in relation to major and clinically significant non-major bleeding.
- Open Access
- 30 October 2022
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 10 (4) , 371-386-386
MODERN DIRECTED ANTIVIRAL COVID-19 THERAPY: RESULTS OF MULTICENTER CLINICAL EFFECTIVENESS AND SAFETY STUDY OF FIXED NIRMATRELVIR+RITONAVIR COMBINATION
The article presents the data from an open, two-stage, multicenter study on the efficacy and safety evaluation of a combined drug (a fixed combination of nirmatrelvir 300 mg and ritonavir 100 mg) in the complex therapy in COVID-19 patients.The aim of the study was to assess the safety, tolerability and pharmacokinetic parameters of the fixed combination of nirmatrelvir 300 mg and ritonavir 100 mg in healthy volunteers, the efficacy and safety assessment of the drug in the combination therapy compared with the standard therapy in COVID-19 patients.Material and methods. An open two-stage multicenter clinical study to assess the main pharmacokinetic parameters, safety, and efficacy against COVID-19 of the drug nirmatrelvir 300 mg and ritonavir 100 mg combination (Skyvira® PROMOMED RUS LLC, Russia) in the adult population, included 2 stages. At stage 1, safety, tolerability and pharmacokinetic parameters were evaluated in healthy volunteers (over 18 years of age) in order to confirm their comparability with the literature data known for a set of active substances. Phase 2 assessed efficacy and safety in COVID-19 patients. As a part of the second stage, the study involved 264 patients (men and women aged 18 to 80 years), who had been divided into two groups. The first group patients (n=132) received the study drugs (nirmatrelvir 300 mg and ritonavir 100 mg) – 1 tablet twice a day with an interval of 12±2 hours for 5 days in combination with pathogenetic and symptomatic therapy. The second group patients (n=132) received standard therapy in accordance with the approved Temporary Guidelines for the Prevention and Treatment of Novel Coronavirus Infection (Version 15 dated February 22, 2022).Results. During the study, none of the patients from the (nirmatrelvir + ritonavir) group experienced a transition of the COVID-19 course to a heavier severity level, in contrast to the patients in the standard therapy group. The study participants included patients with comorbidities (68% of the general population), with risk factors for COVID-19 progression to a heavier severity level and the risk of hospitalization (75% of the general population). There were no cases of COVID-19 progression to a heavier severity level in the study drug group. By the 6th day, in the nirmatrelvir + ritonavir group, the proportion of the patients who had achieved a complete recovery was twice more and amounted to 35.61% (p=0.0001), and the proportion of the patients with a negative RNA analysis to SARS-CoV-2 was 20% higher than in the comparison group, and amounted to 82.58% (p=0.0001). The fixed nirmatrelvir + ritonavir combination therapy has a favorable safety profile comparable to the standard therapy. The identified adverse reactions were transient in nature and did not require discontinuation of therapy or changes in the treatment regimen.Conclusion. The fixed nirmatrelvir + ritonavir combination has a favorable safety profile in COVID-19 patients, comparable to the standard therapy. The data obtained demonstrate a clinical and pharmacoeconomic feasibility of including the fixed (nirmatrelvir + ritonavir) combination in the COVID-19 treatment regimen.
- 30 October 2022
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 10 (4) , 371-386-386
Open AccessMODERN DIRECTED ANTIVIRAL COVID-19 THERAPY: RESULTS OF MULTICENTER CLINICAL EFFECTIVENESS AND SAFETY STUDY OF FIXED NIRMATRELVIR+RITONAVIR COMBINATION
The article presents the data from an open, two-stage, multicenter study on the efficacy and safety evaluation of a combined drug (a fixed combination of nirmatrelvir 300 mg and ritonavir 100 mg) in the complex therapy in COVID-19 patients.The aim of the study was to assess the safety, tolerability and pharmacokinetic parameters of the fixed combination of nirmatrelvir 300 mg and ritonavir 100 mg in healthy volunteers, the efficacy and safety assessment of the drug in the combination therapy compared with the standard therapy in COVID-19 patients.Material and methods. An open two-stage multicenter clinical study to assess the main pharmacokinetic parameters, safety, and efficacy against COVID-19 of the drug nirmatrelvir 300 mg and ritonavir 100 mg combination (Skyvira® PROMOMED RUS LLC, Russia) in the adult population, included 2 stages. At stage 1, safety, tolerability and pharmacokinetic parameters were evaluated in healthy volunteers (over 18 years of age) in order to confirm their comparability with the literature data known for a set of active substances. Phase 2 assessed efficacy and safety in COVID-19 patients. As a part of the second stage, the study involved 264 patients (men and women aged 18 to 80 years), who had been divided into two groups. The first group patients (n=132) received the study drugs (nirmatrelvir 300 mg and ritonavir 100 mg) – 1 tablet twice a day with an interval of 12±2 hours for 5 days in combination with pathogenetic and symptomatic therapy. The second group patients (n=132) received standard therapy in accordance with the approved Temporary Guidelines for the Prevention and Treatment of Novel Coronavirus Infection (Version 15 dated February 22, 2022).Results. During the study, none of the patients from the (nirmatrelvir + ritonavir) group experienced a transition of the COVID-19 course to a heavier severity level, in contrast to the patients in the standard therapy group. The study participants included patients with comorbidities (68% of the general population), with risk factors for COVID-19 progression to a heavier severity level and the risk of hospitalization (75% of the general population). There were no cases of COVID-19 progression to a heavier severity level in the study drug group. By the 6th day, in the nirmatrelvir + ritonavir group, the proportion of the patients who had achieved a complete recovery was twice more and amounted to 35.61% (p=0.0001), and the proportion of the patients with a negative RNA analysis to SARS-CoV-2 was 20% higher than in the comparison group, and amounted to 82.58% (p=0.0001). The fixed nirmatrelvir + ritonavir combination therapy has a favorable safety profile comparable to the standard therapy. The identified adverse reactions were transient in nature and did not require discontinuation of therapy or changes in the treatment regimen.Conclusion. The fixed nirmatrelvir + ritonavir combination has a favorable safety profile in COVID-19 patients, comparable to the standard therapy. The data obtained demonstrate a clinical and pharmacoeconomic feasibility of including the fixed (nirmatrelvir + ritonavir) combination in the COVID-19 treatment regimen.
- Open Access
- 9 March 2022
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 10 (1) , 113-126-126
EFFECTIVENESS AND SAFETY OF FAVIPIRAVIR INFUSION IN PATIENTS HOSPITALIZED WITH COVID-19
Research in the development of new therapeutic agents with a wide spectrum of the antiviral activity and a low ability to develop resistance remains the main dimension in combating the global threat to public health. The need for a parenteral form of favipiravir was dictated by the necessity to increase the efficacy of therapy in COVID-19 inpatients. This dosage form has expanded the possibilities of drug therapy in the inpatients, for whom a therapeutic effect acceleration and a high safety profile of the drugs used are especially important.The aim of the article is the evaluation of the efficacy and safety of a medicinal product containing favipiravir for the parenteral administration against the background of pathogenetic and symptomatic therapy, in comparison with standard therapy in hospitalized COVID-19 patients.Materials and methods. An open, randomized, multicenter comparative study was conducted in 6 research centers in the Russian Federation to evaluate the efficacy and safety of favipiravir, a lyophilisate for the preparation of a concentrate for the infusion solution administrated to the patients hospitalized with COVID-19. Screening procedures and randomization were completed in 217 patients, 209 of which had completed the study in accordance with the protocol.Results. Between the study groups, statistically significant differences have been found out, making it possible to consider the hypothesis of the drug Areplivir (favipiravir) superiority for the parenteral administration over the standard therapy, which included favipiravir (p. o.) and remdesivir. A comparative analysis has shown that a course of therapy with the parenteral favipiravir drug leads to a significant improvement in the condition of patients with COVID-19, significant benefits in terms of the speed and frequency of improvement in the clinical status of patients, as well as a reduction in the hospital stay length. It has been proven that therapy with a drug containing favipiravir for the parenteral administration does not adversely affect the parameters of clinical and biochemical blood tests, urinalysis, coagulograms, vital signs and ECG, which indicates the therapy safety. The study drug is characterized by a high safety profile and tolerability.Conclusion. The versatility and resistance to mutations of RNA-dependent RNA polymerase make it possible to consider it as the main target for combating the most common RNA viruses that cause ARVI, that determines the need further studies of favipiravir to expand the range of its indications.
- 9 March 2022
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 10 (1) , 113-126-126
Open AccessEFFECTIVENESS AND SAFETY OF FAVIPIRAVIR INFUSION IN PATIENTS HOSPITALIZED WITH COVID-19
Research in the development of new therapeutic agents with a wide spectrum of the antiviral activity and a low ability to develop resistance remains the main dimension in combating the global threat to public health. The need for a parenteral form of favipiravir was dictated by the necessity to increase the efficacy of therapy in COVID-19 inpatients. This dosage form has expanded the possibilities of drug therapy in the inpatients, for whom a therapeutic effect acceleration and a high safety profile of the drugs used are especially important.The aim of the article is the evaluation of the efficacy and safety of a medicinal product containing favipiravir for the parenteral administration against the background of pathogenetic and symptomatic therapy, in comparison with standard therapy in hospitalized COVID-19 patients.Materials and methods. An open, randomized, multicenter comparative study was conducted in 6 research centers in the Russian Federation to evaluate the efficacy and safety of favipiravir, a lyophilisate for the preparation of a concentrate for the infusion solution administrated to the patients hospitalized with COVID-19. Screening procedures and randomization were completed in 217 patients, 209 of which had completed the study in accordance with the protocol.Results. Between the study groups, statistically significant differences have been found out, making it possible to consider the hypothesis of the drug Areplivir (favipiravir) superiority for the parenteral administration over the standard therapy, which included favipiravir (p. o.) and remdesivir. A comparative analysis has shown that a course of therapy with the parenteral favipiravir drug leads to a significant improvement in the condition of patients with COVID-19, significant benefits in terms of the speed and frequency of improvement in the clinical status of patients, as well as a reduction in the hospital stay length. It has been proven that therapy with a drug containing favipiravir for the parenteral administration does not adversely affect the parameters of clinical and biochemical blood tests, urinalysis, coagulograms, vital signs and ECG, which indicates the therapy safety. The study drug is characterized by a high safety profile and tolerability.Conclusion. The versatility and resistance to mutations of RNA-dependent RNA polymerase make it possible to consider it as the main target for combating the most common RNA viruses that cause ARVI, that determines the need further studies of favipiravir to expand the range of its indications.